» Articles » PMID: 17610546

RCTs and Observational Studies to Determine the Effect of Prophylaxis in Severe Haemophilia

Overview
Journal Haemophilia
Specialty Hematology
Date 2007 Jul 6
PMID 17610546
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

It has been suggested that more RCTs should be conducted in the evaluation of haemophilia treatment, including prophylaxis. To draw valid conclusions from experimental or observational studies, internal validity should be ensured. In particular, similarity of prognosis between treatment groups compared in a particular study is needed. Because the use of prophylaxis in observational studies is nonrandomized by definition, special efforts should be made to achieve comparability of prognosis, that is, to avoid 'confounding by indication'; in RCTs this is ensured by randomized allocation of treatment. However, the high costs of an RCT results in a limitation of both patient numbers and length of follow up. Observational studies tend to be more generalizable and cheaper, as they may include a wider spectrum of morbidities, use treatment protocols in agreement with routine care, and use available data. Therefore, observational studies can be much larger and of longer duration than RCTs; and are the preferred design for the evaluation of long term treatment effects. Several valid observational studies comparing prophylaxis and on demand treatment have reported both a short term reduction of 75-90% in bleeding frequency, and significant improvement in arthropathy, quality of life, and socioeconomic parameters after more than 20 years of prophylactic treatment. RCTs provide the most powerful tool for the evaluation of short term effects of any treatment, but are infeasible for the evaluation of long term effects. The definitive assessment of the long-term benefits of prophylaxis requires observational studies that should be performed according to rigorous standards.

Citing Articles

Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.

Pochopien M, Tytula A, Toumi M, Falk A, Martone N, Hakimi Z Adv Ther. 2024; 41(6):2307-2323.

PMID: 38652439 PMC: 11133064. DOI: 10.1007/s12325-024-02841-w.


Impact of prophylaxis on health-related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries.

Usuba K, Price V, Blanchette V, Abad A, Altisent C, Buchner-Daley L Res Pract Thromb Haemost. 2019; 3(3):397-404.

PMID: 31294327 PMC: 6611476. DOI: 10.1002/rth2.12202.


Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.

Berger K, Feldman B, Wasserman J, Schramm W, Blanchette V, Fischer K Haematologica. 2016; 101(3):266-8.

PMID: 26928247 PMC: 4815717. DOI: 10.3324/haematol.2015.139931.


Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Fischer K, Steen Carlsson K, Petrini P, Holmstrom M, Ljung R, van den Berg H Blood. 2013; 122(7):1129-36.

PMID: 23777770 PMC: 3744988. DOI: 10.1182/blood-2012-12-470898.


A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.

Fischer K, Pouw M, Lewandowski D, Janssen M, van den Berg H, van Hout B Haematologica. 2011; 96(5):738-43.

PMID: 21273268 PMC: 3084921. DOI: 10.3324/haematol.2010.029868.